The first human pharmacokinetics study of Neurotech International’s broad-spectrum cannabinoid treatment, NTI164, has shown positive results […]
The first human pharmacokinetics study of Neurotech International’s broad-spectrum cannabinoid treatment, NTI164, has shown positive results […]
